Global Dementia and Movement Disorder Treatment Market 2017-2021
About Dementia and Movement Disorder Treatment
Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality changes, difficulty in performing activities, loss of memory, and aphasia. Dementia can be classified into different types, based on the parts of brain affected. Among these types, Alzheimer’s disease is the most common type of dementia.
Technavio’s analysts forecast the global dementia and movement disorder treatment market to grow at a CAGR of 4.48% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global dementia and movement disorder treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Dementia and Movement Disorder Treatment Market 2017-2021
Technavio recognizes the following companies as the key players in the global dementia and movement disorder treatment market: Allergan, Eisai, Novartis, and Teva Pharmaceutical Industries.
Other Prominent Vendors in the market are: Amgen, Pfizer, UCB, H. Lundbeck, F. Hoffmann-La Roche, and Eli Lilly.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of biomarkers. The global DAMD market is primarily dominated by MAO inhibitors, AChE inhibitors, and glutamate inhibitors. Use of these drugs for the treatment of different types of dementia such as Lewy body dementia and movement disorders such as Parkinson’s disease indicates that these diseases have the same pathological conditions.”
According to the report, one driver in the market is need for disease modifying drugs. The treatment for dementia is currently dominated by therapeutic approaches that are focused on providing symptomatic relief; drugs indicated for the treatment of various types of dementia and movement disorders only treat symptoms and not the underlying cause of the disease. These drugs either belong to the class of anticholinesterase inhibitors or modulate the activity of glutamate on the nervous system. Anticholinesterase inhibitors act by reversible or irreversible inhibition of cholinesterase responsible for the depletion of ACh from the synaptic cleft.
Further, the report states that one challenge in the market is social stigma associated with dementia. Dementia is a neurological condition, characterized by poor cognitive functions, impaired social and occupational functioning, and diminished memory. It is perceived negatively in different parts of the world; the perception varies from it being viewed as a natural consequence of aging or in worse cases inadvertently linked to archaic beliefs. This, in turn, has a negative impact on those with dementia as they often refrain from reporting their symptoms to healthcare providers, leading to low diagnostic rates, thus hampering the market growth. In some parts of the world, public disclosure of such symptoms triggers negative reactions from family and friends leading to a kind of social isolation.
Allergan, Eisai, Novartis, Teva Pharmaceutical Industries, Amgen, Pfizer, UCB, H. Lundbeck, F. Hoffmann-La Roche, and Eli Lilly.